Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 8.16 3.29% 0.26
SYRS closed up 3.29 percent on Friday, November 16, 2018, on 80 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical SYRS trend table...

Date Alert Name Type % Chg
Nov 16 Pocket Pivot Bullish Swing Setup 0.00%
Nov 16 Inside Day Range Contraction 0.00%
Nov 15 Pocket Pivot Bullish Swing Setup 3.29%
Nov 15 Upper Bollinger Band Touch Strength 3.29%
Nov 12 20 DMA Support Bullish 8.80%
Nov 12 Outside Day Range Expansion 8.80%
Nov 9 20 DMA Support Bullish 10.87%
Nov 8 1,2,3 Retracement Bearish Bearish Swing Setup 5.43%
Nov 8 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.43%
Nov 8 Narrow Range Bar Range Contraction 5.43%

Older signals for SYRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.88
52 Week Low 6.25
Average Volume 130,640
200-Day Moving Average 11.1477
50-Day Moving Average 9.2478
20-Day Moving Average 7.4155
10-Day Moving Average 7.767
Average True Range 0.642
ADX 31.17
+DI 17.9901
-DI 21.2009
Chandelier Exit (Long, 3 ATRs ) 6.554
Chandelier Exit (Short, 3 ATRs ) 8.176
Upper Bollinger Band 8.3427
Lower Bollinger Band 6.4883
Percent B (%b) 0.9
BandWidth 25.00708
MACD Line -0.2588
MACD Signal Line -0.4649
MACD Histogram 0.2061
Fundamentals Value
Market Cap 214.28 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -3.87
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.02
Resistance 3 (R3) 8.96 8.61 8.87
Resistance 2 (R2) 8.61 8.40 8.64 8.82
Resistance 1 (R1) 8.39 8.26 8.50 8.45 8.78
Pivot Point 8.04 8.04 8.10 8.07 8.04
Support 1 (S1) 7.82 7.83 7.93 7.88 7.54
Support 2 (S2) 7.47 7.69 7.50 7.50
Support 3 (S3) 7.25 7.47 7.45
Support 4 (S4) 7.31